Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Shaoxing, Yang"'
Autor:
Xiya Ma, Kun Zhang, Jing Xu, Hongjun Gao, Shaoxing Yang, Haifeng Qin, Hong Wang, Fang Gao, Xiaoqing Liu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 20, Pp 1980-1990 (2023)
Abstract Background To dynamically monitor the changes of genomic characteristics during lorlatinib treatment and analyze the resistance profile of lorlatinib in ALK‐positive advanced Chinese patients with non‐small cell lung cancer (NSCLC) with
Externí odkaz:
https://doaj.org/article/bef23a8003964901a7ce80f5336a579f
Autor:
Xiya Ma, Shaoxing Yang, Kun Zhang, Jing Xu, Panpan Lv, Hongjun Gao, Haifeng Qin, Hong Wang, Xiaoqing Liu
Publikováno v:
Thoracic Cancer, Vol 13, Iss 12, Pp 1788-1794 (2022)
Abstract Background The efficacy difference between the second‐ and third‐generation of anaplastic lymphoma kinase‐tyrosine kinase inhibitors (ALK‐TKIs) after crizotinib failure in advanced ALK‐positive non–small cell lung cancer (NSCLC)
Externí odkaz:
https://doaj.org/article/91b1832b31364f358a52f4bad9d67b49
Publikováno v:
Thoracic Cancer, Vol 11, Iss 4, Pp 888-897 (2020)
Background This study aimed to investigate the prognostic value of baseline hemoglobin‐to‐red blood cell distribution width ratio (HRR) in patients with small cell lung cancer (SCLC). Methods We retrospectively analyzed the medical records of pat
Externí odkaz:
https://doaj.org/article/3f46fc5935954b6eb77be2cd0f05511e
Autor:
Panpan Lv, Shaoxing Yang, Wenjing Liu, Haifeng Qin, Xiuhua Tang, Fangfang Wu, Zeyuan Liu, Hongjun Gao, Xiaoqing Liu
Publikováno v:
Thoracic Cancer, Vol 11, Iss 1, Pp 29-40 (2020)
Background Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR‐TKIs) in non‐small cell lung cancer (NSCLC). However, even patients with EGFR‐sensitive mutations in NSCLC have li
Externí odkaz:
https://doaj.org/article/556294ea7a47460893c327cd01bd35fd
Autor:
Guanhua ZHAO, Bin XU, Xiaoyan LI, Chuanhao TANG, Haifeng QIN, Hong WANG, Shaoxing YANG, Weixia WANG, Hongjun GAO, Kun HE, Xiaoqing LIU
Publikováno v:
Chinese Journal of Lung Cancer, Vol 20, Iss 5, Pp 318-325 (2017)
Background and objective Treatment options for patients with squamous cell carcinoma of the lung (SCC) are limited in chemotherapy. However, not all patients could benefit form standard platinum regimen. Considering the dismal prognosis of patients w
Externí odkaz:
https://doaj.org/article/0c551cbbcb994907b6987e18a7c77161
Publikováno v:
Journal of Multidisciplinary Healthcare. 13:1245-1256
Purpose The study aims to investigate and compare the efficacy and safety of intraoperative 125I implantation and postoperative irradiation after surgical decompression and stabilization in the treatment of patients with metastatic epidural spinal co
Publikováno v:
Cancer Management and Research. 12:3409-3417
Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase inhibitor, administered as third-line or further treatment prolonged progression-free survival (PFS) and overall survival (OS) in patients with advanced non-sma
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 4, Pp 888-897 (2020)
Thoracic Cancer, Vol 11, Iss 4, Pp 888-897 (2020)
Background This study aimed to investigate the prognostic value of baseline hemoglobin‐to‐red blood cell distribution width ratio (HRR) in patients with small cell lung cancer (SCLC). Methods We retrospectively analyzed the medical records of pat
Publikováno v:
Chinese Journal of Lung Cancer, Vol 15, Iss 12, Pp 694-700 (2012)
Background and objective CD147, a type of transmembrane glycoprotein embedded on the surface of tumor cells, can promote tumor invasion and metastasis. This aim of this study is to construct a CD147 lentiviral expression vector, establish its stably
Externí odkaz:
https://doaj.org/article/9e7da3ac165f492e8b4f5ccf33efb4ec
Autor:
Fangfang Wu, Zeyuan Liu, Hongjun Gao, Xiuhua Tang, Xiaoqing Liu, Shaoxing Yang, Haifeng Qin, Panpan Lv, Wenjing Liu
Publikováno v:
Thoracic Cancer, Vol 11, Iss 1, Pp 29-40 (2020)
Thoracic Cancer
Thoracic Cancer
Background Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR‐TKIs) in non‐small cell lung cancer (NSCLC). However, even patients with EGFR‐sensitive mutations in NSCLC have li